Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 16/20 | 0.57 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.56 |
| ▸ | G6PD | P11413 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 7/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20842649 | 0.82 | MGLL (0.48) | MGLLTLR9G6PDFAAHHSP90AA1 | |
| SCHEMBL29485045 | 0.82 | MGLL (0.59) | MGLLTLR9G6PDFAAHMAPK1 | |
| SCHEMBL15758049 | 0.78 | NPSR1 (0.56) | MGLLG6PDFAAHHSP90AA1PKM | |
| SCHEMBL10587190 | 0.76 | MGLL (0.57) | MGLLTLR9G6PDFAAHHSP90AA1 | |
| SCHEMBL10587456 | 0.76 | MGLL (0.57) | MGLLTLR9G6PDFAAHHSP90AA1 | |
| SCHEMBL1741609 | 0.76 | TLR9 (0.61) | MGLLTLR9G6PDFAAHHSP90AA1 | |
| SCHEMBL29898506 | 0.76 | TLR9 (0.61) | MGLLTLR9G6PDFAAHHSP90AA1 | |
| SCHEMBL20842699 | 0.76 | MGLL (0.55) | MGLLFAAHHSP90AA1PKMMAPK1 | |
| SCHEMBL20989727 | 0.76 | MGLL (0.47) | MGLLTLR9G6PDFAAHHSP90AA1 | |
| SCHEMBL15758697 | 0.74 | MGLL (0.59) | MGLLFAAHHSP90AA1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11193066-B2 | Polymerizable compound and composition, liquid crystal composite, optical anisotropic body, liquid crystal display device and use thereof | JNC CORPORATION (JP) | 2021-12-07 | — | — | US | disclosed |
| US-20190136135-A1 | POLYMERIZABLE COMPOUND AND COMPOSITION, LIQUID CRYSTAL COMPOSITE, OPTICAL ANISOTROPIC BODY, LIQUID CRYSTAL DISPLAY DEVICE AND USE THEREOF | JNC CORPORATION (JP) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11193066-B2 | Polymerizable compound and composition, liquid crystal composite, optical anisotropic body, liquid crystal display device and use thereof | OCIAD2, PYM1, C1S | MGLL 308/4885TLR9 2154/4885G6PD 4727/4885 |
| US-20190136135-A1 | POLYMERIZABLE COMPOUND AND COMPOSITION, LIQUID CRYSTAL COMPOSITE, OPTICAL ANISOTROPIC BODY, LIQUID CRYSTAL DISPLAY DEVICE AND USE THEREOF | OCIAD2, PYM1, C1S | MGLL 308/4885TLR9 2154/4885G6PD 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.